Drucker Wealth 3.0 LLC acquired a new stake in Cencora, Inc. (NYSE:COR – Free Report) in the second quarter, Holdings Channel.com reports. The firm acquired 5,268 shares of the company’s stock, valued at approximately $1,187,000.
Several other hedge funds also recently bought and sold shares of COR. Vanguard Group Inc. bought a new position in Cencora in the 4th quarter valued at $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new position in Cencora during the first quarter worth about $2,183,619,000. JPMorgan Chase & Co. bought a new position in Cencora in the 1st quarter worth about $1,199,695,000. Boston Partners purchased a new stake in shares of Cencora in the 1st quarter valued at about $1,001,269,000. Finally, Capital Research Global Investors bought a new stake in shares of Cencora during the 1st quarter valued at about $650,424,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Cencora Stock Down 0.9 %
Shares of NYSE:COR opened at $223.43 on Thursday. The stock has a market capitalization of $44.56 billion, a P/E ratio of 24.45, a price-to-earnings-growth ratio of 1.58 and a beta of 0.44. The stock’s 50-day moving average price is $234.93 and its 200-day moving average price is $232.89. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 12-month low of $178.21 and a 12-month high of $247.66.
Cencora Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.91%. The ex-dividend date was Friday, August 9th. Cencora’s payout ratio is 22.32%.
Insider Activity at Cencora
In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. The disclosure for this sale can be found here. Insiders sold 4,450,399 shares of company stock worth $1,070,392,799 in the last three months. 15.80% of the stock is owned by insiders.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Wells Fargo & Company raised their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Leerink Partners reiterated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. JPMorgan Chase & Co. raised their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Finally, Robert W. Baird cut their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $256.67.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Read More
- Five stocks we like better than Cencora
- Investing in Construction Stocks
- Analysts Weigh In: How Will Lower Rates Impact Carvana Stock?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Why AutoZone Stock Could Be Your Next Top Performer
- What Are Dividend Contenders? Investing in Dividend Contenders
- Should You Invest in Treasury Bills?
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.